Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
    1.
    发明授权
    Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same 失效
    杂环大环内酯药剂,其制备方法及其用途

    公开(公告)号:US07576204B2

    公开(公告)日:2009-08-18

    申请号:US10522733

    申请日:2003-07-31

    CPC分类号: C07D407/06

    摘要: A compound represented by the following general formula (I): (I) wherein R7 and R21 are the same or different and each represents optionally substituted C2-22 alkoxy, etc.; a pharmaceutically acceptable salt thereof or hydrates of the same. The compound (1) inhibits angiogenesis and inhibits the production of VEGF particularly under hypoxic conditions, which makes it useful as a remedy for solid cancer.

    摘要翻译: 由以下通式(I)表示的化合物:(I)其中R 7和R 21相同或不同,各自表示任选取代的C 22-22烷氧基等。 其药学上可接受的盐或其水合物。 化合物(1)抑制血管发生并抑制VEGF的产生,特别是在缺氧条件下,其可用作固体癌的治疗剂。

    Novel physiologically active substance
    7.
    发明申请
    Novel physiologically active substance 失效
    新型生理活性物质

    公开(公告)号:US20060235002A1

    公开(公告)日:2006-10-19

    申请号:US10522733

    申请日:2003-07-31

    CPC分类号: C07D407/06

    摘要: A compound represented by the following general formula (I): (I) wherein R7 and R21 are the same or different and each represents optionally substituted C2-22 alkoxy, etc.; a pharmaceutically acceptable salt thereof or hydrates of the same. The compound (1) inhibits angiogenesis and inhibits the production of VEGF particularly under hypoxic conditions, which makes it useful as a remedy for solid cancer.

    摘要翻译: 由以下通式(I)表示的化合物:其中R 7和R 21相同或不同,并且各自表示任选取代的C 2 -22烷氧基等; 其药学上可接受的盐或其水合物。 化合物(1)抑制血管发生并抑制VEGF的产生,特别是在缺氧条件下,其可用作固体癌的治疗剂。